FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy
Recruiting at2 trial locations
NH
Overseen byNezam H Afdhal, M.D.
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Afdhal, Nezam, M.D.
No Placebo Group
Trial Summary
What is the purpose of this trial?
This study will examine the effectiveness of the FibroScan device in differentiating fibrosis in patients with hepatitis B and C. The FibroScan measures liver stiffness and will be correlated to the liver biopsy to see if it can diagnose the stage of liver disease. Patients who are scheduled to have a liver biopsy will also have a fibroscan and the stiffness will be correlated with the biopsy stage.
Research Team
NH
Nezam H Afdhal, M.D.
Principal Investigator
Beth Israel Deaconess Medical Center
Eligibility Criteria
Inclusion Criteria
Subject is able to give informed consent for this study and agrees to provide a blood sample.
Subject must be at least 18 years of age.
Subject has had or will have a liver biopsy for chronic liver disease, secondary to HBV or HCV or within 6 months of FibroScan (experimental cohort 1 only).
See 1 more
Treatment Details
Interventions
- FibroScan (Medical Device)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Single Arm undergoing FibroScanExperimental Treatment1 Intervention
Single arm active comparison of biopsy to vibration controlled elastography
Find a Clinic Near You
Who Is Running the Clinical Trial?
Afdhal, Nezam, M.D.
Lead Sponsor
Trials
1
Recruited
910+
Echosens
Industry Sponsor
Trials
18
Recruited
14,600+